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EVALUATING PHARMACOKINETICS AND PHARMACODYNAMICS OF IN-
TRAVENOUS BUSULFAN IN PEDIATRIC PATIENTS RECEIVING BONE
MARROW TRANSPLANTATION
Kim, A.1, Tse, J.1, Moore, T.B.2. 1 David Geffen School of Medicine at
UCLA, Los Angeles, CA; 2 David Geffen School of Medicine at UCLA,
Los Angeles, CA.
Background: Busulfan (BU) is a commonly used conditioning
agent in bone marrow transplant (BMT). However, it is a narrow
therapeutic index drug which has a strong correlation between
area-under-curve (AUC) and both efficacy and toxicity. Studies in
pediatric patients have suggested that children less than 4 years of
age have a greater clearance and thus lower AUC at standard adult
doses. The goal of this retrospective analysis was to evaluate any
age-related pharmacokinetic and pharmacodynamic differences in
pediatric patients who received BU as a conditioning agent.
Methods: From 2001 to 2006, 21/77 pediatric patients who re-
ceived BMT were reviewed. There were 15 males and 6 females
with a mean age of 6 years. Diagnoses of leukemia (n 5 11), HL
(n5 3), MDS (n5 2), and other (n5 5) were included. 16 patients
received BU 1 cyclophosphamide (CY) while 5 patients received
BU 1 another agent. There were 20 allogeneic and 1 autologous
transplants among which 16 were HLA matched and 5 were mis-
matched. Results: Average BU clearance in patients younger than
4 years old (n 5 8) was 4.1 6 1.0 (ml/min)/kg vs. 3.1 6 0.7 (ml/
min)/kg in patients older than 4 years old (n 5 13) (p 5 0.02).
The corresponding averages for AUC were 998 6 226 mMmin
vs.1155 6 183 mMmin (p 5 0.12). No patients younger than 4
years old developed veno-occlusive disease (VOD) while 5 of the
older patients did (p5 0.044). There were no significant differences
in terms of engraftment, graft-vs-host and relapse. Conclusion:
There were significant age-related pharmacokinetic differences in
pediatric patients less than 4 years of age receiving BU for condi-
tioning prior to BMT. There was a decrease in drug toxicity seen
in these patients. Patients younger than 4 years old might not
need routine pharmacokinetic monitoring.234
CEREBRAL TOXOPLASMOSIS FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) FOR MALIGNANT LYM-
PHOMA: MISINTERPRETATION AS RELAPSED LYMPHOMA ON INITIAL
MRI STUDIES
Froehlich, B., Florax, A., Juergens, H., Groll, A.H., Ehlert, K. Children’s
University Hospital, Muenster, Germany.
Introduction: Infections are a major cause of death in allogeneic
hematopoietic stem cell transplant recipients. Cerebral toxoplas-
mosis is a life-threatening, but fortunately rare protozoal infection
even in this high risk population. Establishment of the correct diag-
nosis may be hindered by non-specific clinical symptoms and un-
characteristic findings in imaging studies. Here, we report the
case of a 15-year-old boy with disseminated anaplastic large cell
lymphoma (ALCL) and post –transplant cerebral toxoplasmosis
misinterpreted as relapsed lymphoma on initial MRI.Case Report:
The 15-year old boy received an allogeneic HSCT from a matched
unrelated donor for treatment of refractory ALCL. Central nervous
system involvement was excluded by normal MRI studies and the
absence of lymphoma cells in cerebrospinal fluid (CSF). Complica-
tions until day1100 included acute GvHD, grade II, viral reactiva-
tions (polyomavirus, CMV and EBV) and a delayed immune system
recovery. Four months post-transplant, he presented with severe
headaches, fever and nausea. A cranial CT scan revealed multiple
hypodense areas in both hemispheres without hemorrhage or evi-
dence of elevated intracranial pressure. Subsequent MR imaging
studies were interpreted as intracerebral relapse of lymphoma.
The patient became somnolent, developed seizures and was admit-
ted to the ICU. A diagnostic work-up was initiated including blood
and CSF cultures, PCR-testing for pathogens in blood and CSF,
a bone marrow aspirate and brain biopsy. Still unaware of the re-
sults, the patient was treated with broad-spectrum antibacterial
drugs, acyclovir, ambisome, rituximab, dexamethasone and pyri-
methamine/sulfadiazine. His condition improved rapidly; cerebral
toxoplasmosis was proven by evidence of a positive PCR in CSFand detection of the pathogen in brain tissue. Another MRI two
weeks later showed the characteristic findings of cerebral toxoplas-
mosis with numerous ring-like contrast-enhancing lesions in both
hemispheres. One year later, the patient still has residual MRI find-
ings, but without neurological abnormalities. He is kept on toxo-
plasmosis maintenance therapy. Conclusion: In hematopoietic
stem cell transplant recipients, a diagnosis of cerebral toxoplasmosis
should be considered in every patient with sudden onset of acute,
neurological symptoms regardless of the presence of characteristic
findings on initial imaging studies.
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LONG TERM FOLLOW-UP IN THREE PEDIATRIC PATIENTS WITH
FARBER DISEASE, TYPE 2/3, FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FROM RELATED AND UNRELATED
DONORS
Ehlert, K.1, Frosch, M.2, Roth, J.2, Juergens, H.1, Vormoor, J.3. 1 Uni-
versity Children’s Hospital, Muenster, Germany; 2 University Children’s
Hospital, Muenster, Germany; 3 Newcastle University, Newcastle upon
Tyne, United Kingdom.
Introduction: Farber Disease (FD) is an autosomal-recessively
inherited, lysosomal storage disorder caused by acid ceramidase de-
ficiency. FD, type 2/3, patients lack central nervous system involve-
ment, their clinical phenotype is dominated by the triad of a hoarse
voice, subcutaneous nodules and inflammatory granuloma around
the joints, resulting in severe, progressive contractures, deviation
of joints and finally considerable impairment of activities of daily
living or even complete immobility. Respiratory tract involvement
leads to death in the third or fourth decade of life. Allogeneic hema-
topoietic stem cell transplantation (HSCT) has been described as
a curative option for these patients. Here, we present the long
term follow-up data of three children after allogeneic HSCT with
encouraging results. Patients and Methods: The three children
were transplanted between May 2001 and February 2004 at the
age of 2, 3 and 4 years, respectively. The patients (female 2, male
1) received an allogeneicHSCT (MRD2,MUD1; stem cell source:
BM 2, PBSC 1) after busulfan-based myeloablative conditioning
regimens. GvHD prophylaxis consisted of CsA and short course
MTXwith (MUD) or without (MRD) rabbit-ATG. Transplant-re-
lated toxicities included acute GvHD, grade II (3), CMV-reactiva-
tion (1), bacterial infections (1) and CsA-associated neurotoxicity
(2). No chronic GvHD has been observed. Donor cell chimerism
is complete in one patient and partial in two patients. The follow-
up period is in a range between three and six years. Following the
first year post-transplant, all children were seen at least twice yearly
by the outpatient pediatric BMT unit and once yearly by pediatric
rheumatology. Pre-transplant all children had severe joint involve-
ment with pain and considerable restriction of motility; post-trans-
plant a rapid improvement and finally resolution of all nodules and
granulomas could be observed without evidence of residual im-
paired function. The children’s mental and motor development is
normal. Routine laboratory and organ function tests, endocrinolog-
ical and neurological studies have yielded normal results. The more
severely affected child with CsA-associated neurotoxicity (stroke
like event with seizures) has recovered completely. Summary: Fol-
low-up evaluation in three children three to six years after allogeneic
HSCT for Farber Disease, type 2/3, has revealed encouraging long-
term results without evidence of relapse, chronic GvHD or late ef-
fects.
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BUSULFAN AND SINGLE-DOSE MELPHALAN AS PREPARATIVE THERAPY
FOR INFANTS AND YOUNG CHILDREN UNDERGOING STEM CELL TRANS-
PLANTATION FOR LEUKEMIA: A SINGLE CENTER EXPERIENCE
Graham, M.L.1, Andreansky, M.1, Katsanis, E.1, Wood, T.S.2,
Hutter, J.J.1. 1 University of Arizona Medical Center, Tucson, AZ;
2 Phoenix Children’s Hospital, Phoenix, AZ.
Between January, 1996 andOctober, 2006, we treated 29 patients
under the age of 4 with ALL (n 5 15), AML (n 5 11), JMML (n 5
2), and CML (n 5 1) with a preparative regimen of Busulfan, 37.5
mg/m2 p.o. q 6 hours for 16 doses and Melphalan 140 to 180 mg/
88 Poster Session Im2. Patients undergoing unrelated donor transplants received an-
tithymocyte globulin, 30 mg/kg, on days -2, -1, and 16. The last
8 Busulfan doses were adjusted to achieve areas under the concen-
tration time curve of 600 – 900micromol.min/liter. Family donor
transplant recipients (n5 9), received Cyclosporine/Methotrexate/
Leukovorin as GVHD prophylaxis; unrelated donor transplant re-
cipients (n 5 19) received Cyclosporine/Steroid prophylaxis; one
patient underwent syngeneic BMT.With a minimum of 12 months
and a median of 66 months follow-up, 19 of the 29 (66%) survive
event-free and 22 of the 29 (76%) survive overall. Five patients re-
lapsed. Three patients in relapse at the time of BMT achieved CR
but relapsed at 5, 5 and 6 months. Two patients with Ph1 ALL re-
lapsed 15 and 26months after BMT and survive event-free 421 and
391 months, respectively, after 2nd transplants with TBI-contain-
ing regimens. One patient with AML in CR2 suffered rejection of
an unrelated cord blood but survives event-free 631 months after
autologous stem cell infusion. Four died of transplant-related com-
plications (multi-organ failure, disseminated adenovirus infection,
enterococcal sepsis, and hemolytic-uremic syndrome with Aspergil-
losis). Toxicity was considerable and included mucositis requiring
parental nutrition (29 of 29), hemolytic uremic syndrome (n 5 5),
pulmonary hemorrhage (n5 3), veno-occlusive disease (n5 3), sei-
zures (n 5 1).
Our data suggest that although this is a moderately toxic regimen,
Busulfan/Melphalan shows promising activity as preparative ther-
apy for infants and very young children with leukemias, avoids total
body irradiation, and produces outcomes similar to those previously
reported for patients in this age group.
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UNRELATED DONOR CORD BLOOD STEM CELL TRANSPLANTATION FOR
LEUKOCYTE ADHESION DEFICIENCY (LAD)
Robertson, K.A., Goebel, W.S., Renbarger, J.L., Jude, V., Gowan, D.,
Towell, P., Lorch, C., Collura, J., Haut, P.R. Indiana Univeristy School
of Medicine-Riley Hospital for Children, Indianapolis, IN.
Leukocyte adhesion deficiency (LAD) is a rare disorder charac-
terized by the congenital absence of CD18 resulting in the loss of
expression of leukocyte CD11/CD18 integrins on myeloid cells
with resultant life threatening infections. Hematopoietic stem cell
transplantation currently provides the only available cure for this
disorder. Although there have been reports of some success in trans-
plantation using related family member donors or unrelated mar-
row donors with either myeloablative or non-myeloablative
prepartative regimens, there is little experience with the use of um-
bilical cord SCT.We present here the first report of a patient trans-
planted with unrelated donor cord blood (UCB) for severe LAD
type 1. The patient was diagnosed at 2 months of age when he pre-
sented with failure to thrive, fever, mastoiditis, and lethargy. Labo-
ratory evaluation revealed a WBC of 165,000 (predominantly
neutrophils) and flow cytometry documented the absence of neutro-
phil expression of CD11b and CD18. He was treated with antibi-
otics and surgical drainage of his mastoid bone. Since no family
donors were identified, and given the need to proceed with trans-
plant expeditiously and to minimize the risk of GVHD, unrelated
donor cord blood transplant was pursued using a non-myeloablative
preparative regimen. A large (16.5  107 TNC/kg and 9.5  105
CD34 cell/kg) 10 of 10 antigen matched unrelated donor cord
blood unit was identified. The preparative regimen included Cam-
path-1H3 (10 mg/d iv days -21 to – 19), fludarabine (30 mg/m2/d iv
days -8 to -4) andmelphalan (140mg/m2 iv day -3). GVHDprophy-
laxis consisted of CSA 1 mycophenolate. He engrafted and was
transfusion independent by day 16. He had no evidence of
GVHD, and donor-host studies revealed 40% donor on day 15.
His donor chimerism fell to 16% by STR on day 41 confirmed
100% recipient by VNTR. His cyclosporine was discontinued
and an extensive viral screen showed no evidence of CMV, EBV,
HHV6, adenovirus, or Hepatitis B. Over the next several months,
his donor chimerism slowly rose to 48% where it has remained sta-
ble for the past 7 months with 44% of his granulocytes positive for
CD11b/CD18. He remains clinically well off all immune suppres-
sion 13 months post-transplant with normal growth and develop-
ment.
Conclusion: UCB is a viable source of stem cells for LAD
patients.238
DURATION OF HOSPITALIZATION IN THE FIRST 100 DAYS FOLLOWING
REDUCED INTENSITY CONDITIONING FOR NON-MALIGNANT DISORDER
TRANSPLANTS IN CHILDREN
Witty, S.1, Barnes, Y.1, Yu, L.2, Gilman, A.3, Nieder, M.4, Adams, R.5,
Dalal, J.6, Pulsipher, M.7, Kamani, N.8, Grimley, M.9, Shenoy, S.1
1 Washington University School of Medicine and St. Louis Children’s Hos-
pital, St. Louis, MO; 2 Louisiana State University, New Orleans, LA;
3 University of North Carolina, Chapel Hill, NC; 4 All Children’s Hospi-
tal, St. Petersburg, FL; 5 Phoenix Children’s Hospital, Phoenix, AZ;
6 Children’s Mercy Hospitals and Clinics, Kansas City, MO; 7 Primary
Children’s Medical Center, Salt Lake City, UT; 8 National Medical Cen-
ter, Washington, DC; 9 Methodist Children’s Hospital of South Texas,
San Antonio, TX.
Background and Objective: A novel reduced intensity condi-
tioning (RIC) regimen was used for hematopoietic stem cell trans-
plantation (HSCT) in childhood non-malignant disorders in an
effort to reduce regimen related organ toxicities and the incidence
and severity of graft-versus-host disease (GVHD). Recipient immu-
nosuppression was used to achieve donor cell engraftment and post-
transplant monitoring included infection surveillance until immune
reconstitution. This retrospective study evaluates duration of hospi-
talization within the first 100 days following HSCT in RIC recipi-
ents. Methods: Thirty patients (7 months to 17 years) with
hemoglobinopathies (4), bone marrow failure (7), immune dysfunc-
tion (11), metabolic disorders (7), and mitochondrial myopathy (1)
underwent HSCT following conditioning with alemtuzumab (48
mg; day -21 to -19), fludarabine (150 mg/m2; day -8 to -4), and mel-
phalan (140 mg/m2 [24] or 70 mg/m2 [6] on day -3). Doses were
lower for patients\10 kg. Stem cell sources included peripheral
blood (PBSC) (4), cord cells (UCB) (5), and bone marrow (BM)
(21). Seven patients (5 UCB; 2 BM/PBSC) received 1–2 antigen
mismatched products. GVHD prophylaxis included a calcineurin
inhibitor, methotrexate (except in 4 UCB transplants) and methyl
prednisolone. Results: Durations of hospitalization in the first
100 days is shown in Table 1; all had donor cell engraftment.
Median number of in-patient days was 22.5 for the group and
was similar for unrelated and related HSCT (Table 1). UCB re-
cipients stayed longer. Eight patients were hospitalized for .30
days (3 unrelated and 1 related BM, 4 mismatched UCB) for he-
molysis (1), organ failure (3), GVHD (3) and infection. Infections
which required hospitalization included bacteria (6), non-CMV
viruses (3), CMV reactivation (3), CMV disease (2), and C. diffi-
cile (4). Three patients died before day 100 of GVHD (1), pro-
gressive disease (1), and infection (1). Conclusions: Recipients
of this RIC regimen had an acceptable duration of hospitalization
in the first 100 days post-transplant. Infectious complications and
GVHD accounted for prolonged hospitalization (.30 days) in the
majority of patients.Table 1. In-patient stay in the first 100 days following HSCT
Median days of
Recipient Details
(number)
hospitalization
(range)
Mean days of
hospitalizationTotal (30) 22.5 (12–88) 29.5
Alive beyond 100 days
(27)22 (12–84) 27Died prior to day 100 (3) 51 (18–88) 51.7
UCB (all unrelated,
mismatched) (5)46 (21–88) 50.3BM 1 PBSC recipients
(25)21.5 (12–84) 26.3Unrelated BM or PBSC
(HLA-matched) (11)27 (14–84) 32.1Unrelated BM or PBSC
(mismatched) (2)20 (15–25) 20Matched related donors
(12)21 (12–42) 21.8
